ARCHIVES

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: New Mount Sinai Cancer Center Gets $7 Million; Jules Harris Named Rush Cancer Center Director

July 25, 1986

FDA Approves Erbitux for Head & Neck Cancer.

March 3, 2006

In Brief: BRI Gets New FCRF Basic Research Contract; Senate Subcommittee Less Generous Than House

October 2, 1987

Two New Modalities Promising For Relapsed/Refractory NHL

January 28, 2005

Analysis Finds Exercise Lowers Colon Cancer Risk

February 27, 2009

Institute of Medicine Elects 70 Members at Annual Meeting

October 25, 2013